Luteinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis

Peptides

Volumn 20, Issue 10, 1999, Pages 1247-1262

  Schally, Andrew V ^a  

^a Endocrine   (United States)

Author keywords

Breast and prostate cancer; Cytotoxic LH RH analogs; Endometrial; LH RH agonists and antagonists; Ovarian

Indexed keywords

ANDROGEN; CETRORELIX; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADOTROPIN; SEX HORMONE;

BREAST CANCER; CARCINOGENESIS; ENDOMETRIUM CANCER; FEMALE GENITAL TRACT TUMOR; GONAD; HORMONE STRUCTURE; HYPOPHYSIS; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REPRODUCTION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MOLECULAR STRUCTURE; PROSTATIC NEOPLASMS;

EID: 0032739426     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(99)00130-8     Document Type: Review

References (185)

1. Ahmann F.R., Citrin D.L., Haan H.A., de Guinan P., Jordan V.C., Kreis W., Scott M., Trump D.L. Zoladex. A sustained-release monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. J Clin Oncol. 5:1987;912-917.
2. Albano C., Smitz H., Camus M., Riethmüller-Winzen H., van Steirteghem A., Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril. 67:1997;917-922.
3. Ayalon D., Ben-David M., Wohl R., Jaffe R., Vagman I., Echstein N., Limor R., Comaru-Schally A.M., Schally A.V. Induction of ovulation with [D-Trp6]LHRH combined with purified FSH in patients with polycystic ovarian disease. Gynecol Endocrinol. 2:1988;319-330.
4. Baba Y., Matsuo H., Schally A.V. Structure of the porcine LH- and FSH-releasing hormone. II. Confirmation of the proposed structure by conventional sequential analysis. Biochem Biophys Res Commun. 44:1971;459-463.
5. Bajusz S., Csernus V.J., Janaky T., Bokser L., Fekete M., Schally A.V. New antagonists of LHRH. II. Inhibition and potentiation of LHRH by closely related analogs. Int J Peptide Prot Res. 32:1988;425-435.
6. Bajusz S., Janaky T., Csernus V.J., Bokser L., Fekete M., Srkalovic G., Redding T.W., Schally A.V. Highly potent analogs of luteinizing hormone-releasing hormone containing D-phenylalanine nitrogen mustard in position 6. Proc Natl Acad Sci USA. 86:1989;6318-6322.
7. Behre H.M., Böckers A., Schlingheider A., Nieschlag E. Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men. Clin Endocrinol. 40:1994;241-248.
8. Behre H.M., Klein B., Steinmeyer E., McGregor G.P., Voigt K., Nieschlag E. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist Cetrorelix (SB-75) in normal men. J Clin Endocrinol Metab. 75:1992;393-398.
9. Behre H.M., Kliesch S., Pühse G., Reissmann T., Nieschlag E. High loading and low maintenance doses of a gonadotropin-releasing hormone antagonist effectively suppress serum luteinizing hormone, follicle-stimulating hormone, and testosterone in normal men. J Clin Endocrinol Metab. 82:1997;1403-1408.
10. Behre H.M., Nashan D., Hubert W., Nieschlag B. Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. J Clin Endocrinol Metab. 74:1992;84-90.
11. Belchetz P.E., Plant T.M., Nakai Y., Keogh E.J., Knobil E. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science. 202:1978;631-633.
12. Benson C. Jr, Crawford E.D., Eisenberger M.A., McLeod D.G., Spaulding J.T., Dorr F.A. National Cancer Institute study of luteinizing hormone-releasing hormone plus flutamide versus luteinizing hormone-releasing hormone plus placebo. Semin Oncol. 18:(Suppl 6):1991;9-12.
13. Bergquist C., Nillius S.J., Wide L. Intranasal gonadotrophin-releasing hormone agonist as a contraceptive agent. Lancet. 2:1979;215-216.
14. Bhasin S., Heber D., Steiner B.S., Handelsman D.J., Swerdloff R.A. Hormonal effects of gonadotropin-releasing hormone (GnRH) agonist in the human male. III. Effects of long term combined treatment with GnRH agonist and androgen. J Clin Endocrinol Metab. 60:1985;998-1003.
15. Bruckner H.W., Motwani B.T. Treatment of advanced refectory ovarian carcinoma with a gonadotropin-releasing hormone analogue. Am J Obstet Gynecol. 161:1989;1216-1218.
16. Burgus R., Butcher M., Amoss M., Ling N., Monahan M., Rivier J., Fellows R., Blackwell R., Vale W., Guillemin R. Primary structure of the ovine hypothalamic luteinizing hormone-releasing factor (LRF). Proc Natl Acad Sci USA. 69:1972;278-282.
17. Canales E.S., Montvelinsky H., Zarate A., Kastin A.J., Coy D.H., Schally A.V. Suppressive effect of an inhibitory LHRH analog on the gonadotropin response to LHRH in normal women. Int J Fertil. 25:1980;190-192.
18. Chang R.J., Laufer L.H., Meldrum D.R., de Fasio J., Lu J.K.H., Vale W.W., Rivier J.W., Judd H.L. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J Clin Endocrinol Metab. 56:1984;897-903.
19. Comaru-Schally A.M., Brannan W., Schally A.V., Colcolough M., Monga M. Efficacy and safety of luteinizing hormone-releasing hormone antagonist Cetrorelix in the treatment of symptomatic benign prostatic hyperplasia. J Clin Endocrinol Metab. 83:1998;3826-3831.
20. Comite F., Pescovitz O.H., Rieth K.G., Dwyer A.J., Hench K., McNemar A., Loriaux D.L., Cutler G.B. Jr. Luteinizing hormone-releasing hormone analog treatment of boys with hypothalamic hamartoma and true precocious puberty. J Clin Endocrinol Metab. 58:1984;888-892.
21. Conn P.M., Crawley W.F. Gonadotropin-releasing hormone and its analogs. N Engl J Med. 324:1991;93-103.
22. Corbin A, Beattie CW, Tracy J, Jones R, Foell TJ, Yardley J, Rees RWA. The anti-reproductive pharmacology of LHRH and the antagonistic analogs. Int J Fertil 1976:81-92.
23. Cortes-Prieto J., Lledo A., Avila C., Cortes-Garcia L., D'Acunto A., Luisi M., Comaru-Schally A.M., Schally A.V. Long-acting agonists of LH-RH in the treatment of large ovarian endometriomas. Int J Fertil. 32:1987;290-297.
24. Coy D.H., Vilchez-Martinez J.A., Coy E.J., Schally A.V. Analogs of luteinizing hormone-releasing hormone with increased biological activity produced by D-amino acid substitutions in position 6. J Med Chem. 19:1976;423-425.
25. Crawford E.D. Hormonal therapy of prostatic carcinoma. Defining the challenge. Cancer. 66:1990;1035-1038.
26. Crawford E.D., Eisenberger M.A., McLeod D.G., Spaulding J.T., Benson R., Dorr F.A., Blumenstein B.A., Davis M.A., Goodman P.J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 321:1989;419-424.
27. Crowley W.F. Jr, Comite F., Vale W., Rivier J., Loriaux D.L., Cutler G.B. Jr. Therapeutic use of pituitary desensitization with a long-acting LHRH agonist a potential new treatment for idiopathic precocious puberty . J Clin Endocrinol Metab. 52:1981;370-372.
28. Diedrich K., Diedrich C., Santos E., Zoll C., Al-Hasani S., Reissmann T., Krebs D., Klingmuller D. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod. 9:1994;788-791.
29. Dondi D., Limonta P., Moretti R.M., Marrelli Montagnani M., Garattini E., Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145 evidence for an autocrine-inhibitory LHRH loop . Cancer Res. 54:1994;4091-4095.
30. Dubourdieu S., Charbonnel B., d'Acremont M.F., Carreau S., Spitz I.M., Bouchard P. Effect of administration of a gonadotropin-releasing hormone (GnRH) antagonist (Nal-Glu) during the periovulatory period the luteinizing hormone surge requires secretion of GnRH . J Clin Endocrinol Metab. 78:1994;343-347.
31. Dutta A.N. Luteinizing hormone-releasing hormone (LHRH) agonists. Drugs Future. 13:1988;43-57.
32. Dutta A.N. Luteinizing hormone-releasing hormone (LHRH) antagonists. Drugs Future. 13:1988;761-787.
33. Eidne K.A., Flanagan C.A., Harris N.S., Millar R.P. Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. J Clin Endocrinol Metab. 64:1987;425-432.
34. Emons G., Müller V., Ortmann O., Schulz K.D. Effects of LHRH-analogs on mitogenic signal transduction in cancer cells. J Steroid Biochem Mol Biol. 65:1998;199-206.
35. Emons G., Ortmann O., Becker M., Irmer G., Springer B., Laun R., Hölzel F., Schulz K.D., Schally A.V. High affinity binding and direct antiproliferative effects of LH-RH analogs in human ovarian cancer cell lines. Cancer Res. 53:1993;5439-5446.
36. Emons G., Ortmann O., Schulz K.D., Schally A.V. Growth-inhibitory actions of analogs of luteinizing hormone releasing hormone on tumor cells. Trends Endocrinol Metab. 8:1997;355-362.
37. Emons G., Ortmann O., Teichert H.M., Fassl H.G., Löhrs U., Kullander S., Kauppila A., Ayalon D., Schally A.V., Oberheuser F. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer - A prospective double-blind randomized trial. Cancer. 78:1996;1452-1460.
38. Emons G., Pahwa G.S., Brack C., Sturm R., Oberheuser F., Knuppen R. Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol. 25:1989;215-221.
39. Emons G., Schally A.V. The use of luteinizing hormone releasing hormone agonists and antagonists in gynaecological cancers. Reproduction. 9:1994;1364-1379.
40. Emons G., Schröder B., Ortmann O., Westphalen S., Schulz K.D., Schally A.V. High affinity binding and direct antiproliferative effects of LH-RH analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab. 77:1993;1458-1464.
41. Fekete M., Wittliff J.L., Schally A.V. Characteristics and distribution of receptors for [D-Trp6]-luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor and sex steroids in 500 biopsy samples of human breast cancer. J Clin Lab Anal. 3:1989;137-147.
42. Felberbaum R.E., Germer U., Ludwig M., Riethmüller-Winzen H., Heise S., Buttge I., Bauer O., Reissmann T., Engel J., Diedrich K. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix. Hum Reprod. 13:1998;1660-1668.
43. Filicori M., Flamigni C., Campaniello E., Merggiola M.C., Michelacci L., Valdiserri A., Ferrari P. Polycystic ovary syndrome abnormalities and management with pulsatile gonadotropin-releasing hormone and gonadotropin-releasing hormone analog . Am J Obstet Gynecol. 163:1990;1737-1742.
44. Filicori M., Hall D.A., Loughlin J.S., Rivier J., Vale W., Crowley F.W. A conservative approach to the management of uterine leiomyomas pituitary desensitization by a luteinizing hormone-releasing hormone analogue . Am J Obstet Gynecol. 147:1983;726-727.
45. Friess H., Büchler M., Krüger M., Beger H.G. Treatment of duct carcinoma of the pancreas with the LH-RH analogue Buserelin. Pancreas. 7:1992;516-521.
46. Fujino M., Fukuda T., Shinagawa S., Kobayashi S., Yamazaki I., Nakayama R., Seely J.H., White W.F., Rippel R.H. Synthetic analogs of luteinizing hormone-releasing hormone (LHRH) substituted in positions 6 and 10. Biochem Biophys Res Commun. 57:1974;1248-1256.
47. Gabrilove J.L., Levine A.C., Kirschenbaum A., Droller M. Effect of a GnRH analogue (leuprolide) on benign prostatic hypertrophy. J Clin Endocrinol Metab. 64:1986;1331-1333.
48. Gallagher C.J., Oliver R.T.D., Oram D.H., Fowler C.G., Blake P.R., Mantell B.S., Slevin M.L., Hope-Stone H.F. A new treatment for endometrial cancer with gonadotropin-releasing hormone analogue. Br J Obstet Gynaecol. 98:1991;1037-1041.
49. George M., Lhomme C., Lefort J., Gras C., Comaru-Schally A.M., Schally A.V. Long-term use of an LH-RH agonist in the management of uterine leiomyomas a study of 17 cases . Int J Fertil. 34:1989;19-24.
50. Gonzalez-Barcena D., Bañuelos-Alvarez R., Perez-Ochoa E., Cardenas-Cornejo I., Comaru-Schally A.M., Schally A.V., Engel J., Reissmann T., Riethmüller-Winzen H. Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix. Hum Reprod. 12:1997;2028-2035.
51. Gonzalez-Barcena D., Ibarra-Olmos M.A., Garcia-Carrasco F., Gutierrez-Samperio C., Comaru-Schally A.M., Schally A.V. Influence of D-Trp6-LH-RH on the survival time in patients with advanced pancreatic cancer. Biomed Pharmacother. 43:1989;313-317.
52. Gonzalez-Barcena D., Kastin A.J., Coy D.H., Nikolics K., Schally A.V. Suppression of gonadotropin release in man by an inhibitory analogue of luteinizing hormone-releasing hormone. Lancet. 2:1977;997-998.
53. Gonzalez-Barcena D., Schally A.V., Comaru-Schally A.M., Cortez-Morales A., Vadillo-Buenfil M., Molina-Ayala M.A. Treatment of patients with advanced prostate cancer with LH-RH antagonist Cetrorelix. Filicori M., Flamigni C. Treatment with GnRH Analogs Controversies & Perspectives. Proceedings of a Satellite Symposium of 15th World Congress of Fertility and Sterility. Bologna, Italy, September 15-16, 1995 . 1996;139-144 Parthenon, Carnforth, UK.
54. Gonzalez-Barcena D., Vadillo-Buenfil M., Cortez-Morales A., Fuentes-Garcia M., Cardenas-Cornejo I., Comaru-Schally A.M., Schally A.V. Luteinizing hormone-releasing hormone antagonist SB-75 (Cetrorelix) as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology. 45:1995;275-281.
55. Gonzalez-Barcena D., Vadillo-Buenfil M., Garcia-Procel E., Guerra-Arguero L., Cardenas-Cornejo I., Comaru-Schally A.M., Schally A.V. Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75). Eur J Endocrinol. 131:1994;286-292.
56. Gonzalez-Barcena D., Vadillo-Buenfil M., Gomez-Orta F., Fuentes Garcia M., Cardenas-Carnejo I., Graef-Sanchez A., Comaru-Schally A.M., Schally A.V. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer. Prostate. 24:1994;84-92.
57. Gudmundsson J.A., Nillius S.J., Bergquist C. Inhibition of ovulation by intranasal Nafarelin, a new superactive agonist GnRH. Contraception. 30:1984;107-114.
58. Hall L.L.H., Malone J.M., Ginsburg K.A. Flare-up of endometriosis induced by gonadotropin-releasing hormone agonist leading to bowel obstruction. Fertil Steril. 64:1995;1204-1206.
59. Halmos G, Arencibia JM, Schally AV, Davis R, Bostwick DG. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 1999 (in press).
60. Halmos G., Nagy A., Lamharzi N., Schally A.V. Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high-affinity to human breast cancers. Cancer Lett. 136:1999;129-136.
61. Happ J., Sennerich T., Krause U., Beyer J. Pernasal gonadorelin (GNRH) analog therapy in a boy with early puberty. Neuroendocrinol Lett. 5:1981;255-260.
62. Hayes F.J., Taylor A.E., Martin K.A., Hall J.E. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe of polycystic ovary syndrome Assessment of neuroendocrine and androgen dynamics . J Clin Endocrinol Metab. 83:1998;2343-2349.
63. Healy D.L., Fraser H.M., Lawson S.L. Shrinkage of a uterine fibroid after subcutaneous infusion of a LHRH agonist. Br Med J. 289:1984;1267-1268.
64. Heber D., Swerdloff R.S. Male contraception synergism of gonadotropin-releasing hormone analog and testosterone in suppressing gonadotropin . Science. 209:1980;936-938.
65. Henzl M.R., Corson S.L., Moghissi K., Buttram V.C., Bergquist C., Jacobson J. Administration of nasal Nafarelin as compared with oral danazol for endometriosis a multicenter double-blind comparative clinical trial . N Engl J Med. 318:1988;485-489.
66. Hershkovitz E., Marbach M., Bosin E., Levy J., Roberts C.T. Jr, LeRoith D., Schally A.V., Sharoni Y. Luteinizing hormone-releasing hormone antagonists interfere with autocrine and paracrine growth stimulation of MCF-7 mammary cancer cells by insulin-like growth factor. J Clin Endocrinol Metab. 77:1993;963-968.
67. Irmer G., Bürger C., Müller R., Ortmann O., Peter U., Kakar S.S., Neill J.D., Schulz K.D., Emons G. Expression of the messenger ribonucleic acids for luteinizing hormone-releasing hormone and its receptor in human ovarian epithelial carcinoma. Cancer Res. 55:1995;817-822.
68. Irmer G., Bürger C., Ortmann O., Schulz K.D., Emons G. Expression of luteinizing hormone-releasing hormone and its mRNA in human endometrial cancer cell lines. J Clin Endocrinol Metab. 79:1994;916-919.
69. Itskovitz-Eldor J., Kol S., Mannaerts B., Coelingh Bennink H. First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462). Hum Reprod. 13:1998;294-295.
70. Jiang G., Miller C., Koerber S.C., Porter J., Craig A.G., Bhattacharjee S., Kraft P., Burris T.P., Campen C.A., Rivier C.L., Rivier J.E. Betidamino acid scan of the GnRH antagonist Acyline. J Med Chem. 40:1997;3739-3748.
71. Johnson B., Gendrich R.L., White W.F. Delay of puberty and inhibition of reproductive processes in the rat by a gonadotropin-releasing hormone agonist analog. Fertil Steril. 27:1976;853-860.
72. Jungwirth A., Galvan G., Pinski J., Halmos G., Szepeshazi K., Cai R.Z., Groot K., Schally A.V. LH-RH antagonist Cetrorelix (SB-75), and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Prostate. 32:1987;164-172.
73. Jungwirth A., Pinski J., Galvan G., Halmos G., Szepeshazi K., Cai R.Z., Groot K., Vadillo-Buenfil M., Schally A.V. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by LH-RH antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer. 33:1997;1141-1148.
74. Jungwirth A., Schally A.V., Halmos G., Groot K., Szepeshazi K., Pinski J., Armatis P. Inhibition of growth of CAKI-I human renal adenocarcinoma in vivo by LH-RH antagonist Cetrorelix, somatostatin analog RC-160 and bombesin antagonist RC-3940-II. Cancer. 82:1998;909-917.
75. Jungwirth A., Schally A.V., Nagy A., Pinski J., Groot K., Galvan G., Szepeshazi K., Halmos G. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. Int J Oncol. 10:1997;877-884.
76. Kahán Z., Nagy A., Schally A.V., Halmos G., Arencibia J.M., Groot K. Complete regression of MX-1 human breast cancer xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207. Cancer. 85:1999;2608-2615.
77. Kakar S.S. Molecular structure of the human gonadotropin-releasing hormone receptor gene. Eur J Endocrinol. 137:1997;183-192.
78. Kakar S.S., Grizzle W.E., Neil J.D. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol. 106:1994;145-149.
79. Kappy M., Stuart T., Perelman A., Clemons R. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (Leuprolide acetate, Lupron depot) in children with precocious puberty. J Clin Endocrinol Metab. 69:1989;1087-1089.
80. Karten M.J., Rivier J.E. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists Rationale and perspective . Endocr Rev. 7:1986;44-66.
81. Kastin A.J., Schally A.V., Gual C., Midgley A.R. Jr, Bowers C.Y., Diaz-Infante A. Jr. Stimulation of LH release in men and women by hypothalamic LH-releasing hormone purified from porcine hypothalami. J Clin Endocrinol Metab. 29:1969;1046-1050.
82. Kastin A.J., Schally A.V., Gual C., Midgley A.R. Jr, Bowers C.Y., Gomez-Perez E. Administration of LH-releasing hormone to selected human subjects. Am J Obstet Gynecol. 108:1970;177-182.
83. Kaufmann M., Jonat W., Kleeburg U., Eirmann W., Janicke F., Hilfrich J., Kreienberg R., Albrecht M., Weitzel H.K., Schmid H., Strunz P., Schachner-Wunschmann E., Bastert G., Maass H. The German Zoladex trial group goserelin, a depot gonadotropin releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer . J Clin Oncol. 7:1989;1113-1119.
84. Kauli R., Pertzelan A., Ben-Zeev Z., Prager-Lewin R., Kaufman H., Comaru-Schally A.M., Schally A.V., Laron Z. Treatment of precocious puberty with LH-RH analogue in combination with cyproterone acetate - further experience. Clin Endocrinol. 20:1984;77-387.
85. Kettel L.M., Murphy A.A., Morales A.J., Rivier J., Vale W., Yen S.S.C. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril. 60:1993;642-646.
86. Kleinman D., Roberts C.T. Jr, LeRoith D., Schally A.V., Levy J., Sharoni Y. Regulation of endometrial cancer cell growth by insulin-like growth factors and luteinizing hormone-releasing hormone antagonist SB-75. Reg Pept. 48:1993;91-98.
87. Klijn J.G.M., deJong F.H. Treatment with a luteinizing hormone-releasing hormone analogue (Buserelin) in premenopausal patients with metastatic breast cancer. Lancet. 1:1982;1213-1216.
88. Klingmuller D., Schepke M., Enzweiler C., Bidlingmaier F. Hormonal responses to the new potent GnRH antagonist Cetrorelix. Acta Endocrinol. 128:1993;15-18.
89. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res. 36:1980;53-88.
90. Koppán M., Nagy A., Schally A.V., Plonowski A., Halmos G., Arencibia J.M., Groot K. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice. Prostate. 38:1999;151-158.
91. Korkut E., Bokser L., Comaru-Schally A.M., Groot K., Schally A.V. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci USA. 88:1991;844-848.
92. Kuhn J.M., Billebaud T., Navratil H., Moulonguet A., Fiet J., Grise P., Louis J.F., Costa P., Husson J.M., Dahan R., Bertagna C., Edelstein R. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med. 321:1984;413-418.
93. Labrie F., Dupont A., Belanger A., Lachance R. Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol. 138:1987;804-806.
94. Lahlou N., Roger M., Chaussain J.L., Feinstein M.C., Sultan C., Toublanc J.E., Schally A.V., Scholler R. Gonadotropin and α-subunit secretion during long term pituitary suppression by D-Trp6-luteinizing hormone-releasing hormone microcapsules as treatment of precocious puberty. J Clin Endocrinol Metab. 65:1987;946-953.
95. Lamharzi N., Halmos G., Jungwirth A., Schally A.V. Decrease in the level and mRNA expression of LH-RH and EGF receptors after treatment with LH-RH antagonist Cetrorelix in DU-145 prostate tumor xenografts in nude mice. Int J Oncol. 13:1998;429-435.
96. Lamharzi N., Schally A.V., Koppán M. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II in tumors. Reg Pept. 77:1998;185-192.
97. Lamharzi N., Schally A.V., Koppán M., Groot K. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of IGF-II tumors. Proc Natl Acad Sci USA. 95:1998;8864-8868.
98. Lemay A., Quesnel G. Potential new treatment of endometriosis Reversible inhibition of pituitary ovarian function by chronic intranasal administration of luteinizing hormone releasing hormone (LHRH) agonist . Fertil Steril. 38:1982;376-379.
99. Leroy I., d'Acremont M.F., Brailly-Tabard S., Frydman R., de Mouzon J., Bouchard P. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge further evidence for the role of GnRH during the LH surge . Fertil Steril. 62:1994;461-467.
100. Limonta P., Dondi D., Moretti R.M., Maggi R., Motta M. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab. 75:1992;207-212.
101. Limonta P., Pratesi G., Moretti R.M., Montagnani Marelli M., Motta M., Dondi D. Comments on inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II. Eur J Cancer. 34:1998;1134-1135.
102. Linde R., Doelle G.C., Alexander N., Kirchner F., Vale W., Rivier J., Rabin D. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal man. N Eng J Med. 305:1981;663-667.
103. Ljungqvist A., Feng D.M., Hook W., Shen Z.X., Bowers C., Folkers K. Antide and related antagonists of luteinizing hormone release with long action and oral activity. Proc Natl Acad Sci USA. 85:1988;8236-8240.
104. Maheaux R., Guilloteau C., Lemay A., Bastide A., Fazekas A.T.A. Regression of leiomyomata uteri following hypoestrogenism induced by repetitive LHRH agonist treatment preliminary report . Fertil Steril. 42:1984;644-646.
105. Manni A., Santen R., Harvey H., Lipton A., Max D. Treatment of breast cancer with gonadotropin-releasing hormone. Endocr Rev. 7:1986;89-94.
106. Mansfield M.J., Rudlin C.R., Crigler J.F. Jr, Karol K.A., Crawford J.D., Boepple P.A., Crowley W.F. Jr. Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty. J Clin Endocrinol Metab. 66:1988;3-9.
107. Mathé G., Keiling R., Prevot G., Vo Van M.L., Gastiaburu J., Vannetzel J.M., Despax R., Jasmin C., Levi F., Musset M., Machover D., Ribaud R., Misset J.L. LHRH agonist breast and prostate cancer . Klijn J.G.M., Paridaens R., Foekens J.A. Hormonal Manipulation of Cancer Peptides, Growth Factors, and New (Anti) Steroidal Agents . 1987;315-319 Raven Press, New York.
108. Mathé G., Schally A.V., Comaru-Schally A.M., Mauvernay R.Y., Vo Van M.L., Machover D., Misset J.L., Court B., Bouchard P., Duchier J., Morin P., Keiling R., Schwarzenberg L., Kerbrat P., Achille E., Tronc J.C., Fendler J.P., Pappo E., Metz R., Prevot G. Phase II Trial with D-Trp-6-LH-RH in prostatic carcinoma comparison with other hormonal agents . Prostate. 9:1986;327-342.
109. Matsuo H., Arimura A., Schally A.V. Synthesis of the porcine LH- and FSH-releasing hormone by the solid-phase method. Biochem Biophys Res Commun. 45:1971;822-827.
110. Matsuo H., Baba Y., Nair R.M.G., Arimura A., Schally A.V. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun. 43:1971;1334-1339.
111. Meldrum D.R., Chang R.J., Lu J., Vale W., Rivier J., Judd H.L. Medical oophorectomy using a long-acting GnRH agonist a possible new approach to the treatment of endometriosis . J Clin Endocrinol Metab. 54:1982;1081-1083.
112. Miller W.R., Scott W.N., Morris R., Fraser H.M., Sharpe R.M. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature. 313:1985;231-233.
113. Miyazaki M., Nagy A., Schally A.V., Lamharzi N., Halmos G., Szepeshazi K., Groot K., Armatis P. Growth inhibition of human ovarian cancers by cytotoxic analogs of luteinizing hormone-releasing hormone. J Natl Cancer Inst. 89:1997;1803-1809.
114. Miyazaki M., Schally A.V., Nagy A., Lamharzi N., Halmos G., Szepeshazi K., Armatis P. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice. Am J Obstet Gynecol. 180:1999;1095-1103.
115. Molineaux C.J., Sluss P.M., Bree M.P., Gefter M.L., Sullivan L.M., Garnick M.B. Suppression of plasma gonadotropins by Abarelix a potent new LHRH antagonist . Mol Urol. 2:1998;265-268.
116. Monahan M., Rivier J., Burgus R., Amoss M., Blackwell R., Vale W., Guillemin R. Synthèse totale par phase solide d'un décapeptide qui stimule la sécrétion des gonadotropines hypophysaires LH et FSH. C R Acad Sci Paris. 273:1971;508-510.
117. Monsonego J., Destable M.D., de Saint Florent G., Amouroux J., Kouyoumdjian J.C., Haour F., Breau J.L., Israel L., Comaru-Schally A.M., Schally A.V. Fibrocystic disease of the breast in premenopausal women Histohormonal correlation and response to LHRH analog treatment . Am J Obstet Gynecol. 164:1991;1181-1189.
118. Nagy A., Schally A.V., Armatis P., Szepeshazi K., Halmos G., Kovács M., Zarándi M., Groot K., Miyazaki M., Jungwirth A., Horváth J. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent. Proc Natl Acad Sci USA. 93:1996;7269-7273.
119. 2+ mobilizing hormones the case of gonadotropin releasing hormone . Endocr Rev. 11:1990;326-353.
120. Nelson L.R., Fujimoto V.Y., Jaffe R.B., Monroe S.E. Suppression of follicular phase pituitary-gonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix). Fertil Steril. 63:1995;963-969.
121. Nillius S.J., Bergquist C.H., Wide L. Inhibition of ovulation in women by chronic treatment with a stimulatory LHRH analogue - a new approach to birth control? Contraception. 17:1978;537-545.
122. Olivenness F., Fanchin R., Bouchard P., de Ziegler D., Taieb J., Selva J., Frydman R. The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program. Fertil Steril. 62:1994;468-476.
123. Olivenness F., Fanchin R., Bouchard P., Taieb J., Selva J., Frydman R. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day eight of in vitro fertilization cycles a pilot study . Hum Reprod. 10:1995;1382-1386.
124. Parmar H., Lightman S.L., Allen L., Phillips R.H., Edwards L., Schally A.V. Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma. Lancet. 2:1985;1202-1205.
125. Parmar H., Phillips R.H., Rustin G., Hanham I.W., Schally A.V., Lightman S.L. Response to [D-Trp6]LHRH (Decapeptyl) microcapsules in advanced ovarian cancer. Br Med J. 296:1988;1229.
126. Parmar H., Phillips R.H., Rustin C., Lightman S.L., Schally A.V. Therapy of advanced ovarian cancer with D-Trp6-LH-RH (Decapeptyl) microcapsules. Biomed Pharmacother. 42:1988;531-548.
127. Peeling W.B. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology. 33:(Suppl):1989;45-52.
128. Perl V., Marquez J., Schally A.V., Comaru-Schally A.M., Leal G., Zacharias S., Gomez-Lira C. Treatment of leiomyomata uteri with D-Trp6-LHRH. Fertil Steril. 48:1987;383-389.
129. Peters C.A., Walsh P.C. The effect of nafarelin acetate, a luteinizing hormone-releasing hormone agonist, on benign prostatic hyperplasia. N Engl J Med. 317:1987;599-604.
130. Pinski J., Lamharzi N., Halmos G., Groot K., Jungwirth A., Vadillo-Buenfil M., Kakar S.S., Schally A.V. Chronic administration of luteinizing hormone-releasing hormone (LHRH) antagonist Cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats. Endocrinology. 137:1996;3430-3436.
131. Plowman P.N., Nicholson R.I., Walker K.J. Remission of postmenopausal breast cancer during treatment with the luteinizing hormone releasing hormone agonist ICI 118630. Br J Cancer. 54:1986;903-909.
132. Porter R.N., Smith W., Craft I.L., Abdulwabid N.A., Jacobs H.S. Induction of ovulation of in vitro fertilization using Buserelin and gonadotropins. Lancet. 2:1984;1284-1285.
133. Powell J.F.F., Fischer W.H., Park M., Craig A.G., Rivier J.E., White S.A., Francis R.C., Fernald R.D., Licht P., Warby C., Sherwood N.M. Primary structure of solitary form of gonadotropin-releasing hormone (GnRH) in cichlid pituitary three forms of GnRH in brain of cichlid and pumpkinseed fish . Regul Pept. 57:1995;43-53.
134. Qayum A., Gullick W., Clayton R.C., Sikora K., Waxman J. The effect of gonadotrophin releasing hormone analogs in prostate cancer are mediated through specific tumour receptors. Br J Cancer. 62:1990;96-99.
135. Redding T.W., Schally A.V. Inhibition of prostate tumour growth in two rat models by chronic administration of D-Trp6-LH-RH. Proc Natl Acad Sci USA. 78:1981;6509-6512.
136. Redding T.W., Schally A.V. Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA. 80:1983;1459-1462.
137. Redding T.W., Schally A.V., Radulovic S., Milovanovic S., Szepeshazi K., Isaacs J.T. Sustained-release formulations of LH-RH antagonist SB-75 inhibit proliferation and enhance the apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Cancer Res. 52:1992;2538-2544.
138. Redding T.W., Schally A.V., Tice T.R., Meyers W.E. Long-acting delivery systems for peptide inhibition of rat prostate tumours by controlled release of (D-Trp6)- luteinizing hormone-releasing hormone from injectable microcapsules . Proc Natl Acad Sci USA. 81:1984;5845-5848.
139. Reissmann T., Engel J., Kutscher B., Bernd M., Hilgard P., Peukert M., Szeleny I., Reichert S., Gonzalez-Barcena D., Nieschlag E., Comaru-Schally A.M.,
140. Reissmann T., Felberbaum R., Diedrich K., Engel J., Comaru-Schally A.M., Schally A.V. Development and applications of LHRH antagonists in the treatment of infertility - an overview. Hum Reprod. 10:1995;1974-1981.
141. Rivier J.E., Porter J., Rivier C.L., Perrin M., Corrigan A., Hook W.A., Siraganian R.P., Vale W.W. New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro. J Med Chem. 29:1986;1846-1851.
142. Sandow J., von Rechenberg W., Jerzabek G., Stoll W. Pituitary gonadotropins inhibition by a highly active analog of luteinizing hormone-releasing hormone. Fertil Steril. 30:1976;205-209.
143. Santen R.J., Manni A., Harvey H., Redmond C. Endocrine treatment of breast cancer in women. Endocr Rev. 11:1990;221-265.
144. Schally A.V. The use of LHRH analogs in gynecology and tumor therapy. Belfort P., Pinotti J.A., Eskes T.K.A.B. Advances in Gynecology and Obstetrics, General Gynecology, Vol 6. 1989;3-20 Parthenon Publishing, Carnforth, UK.
145. Schally AV. LH-RH analogs. I. Their impact on reproductive medicine. Gynecol Endocrinol 1999 (in press). Special Millenium Edition.
146. Schally AV, Arimura A, Baba Y, Nair RMG, Matsuo H, Redding TW, Debeljuk L, White WF. Purification and properties of the LH and FSH-releasing hormone from porcine hypothalami. Program of the 53rd Meeting of the Endocrine Society, San Francisco, California, June 24-26, 1971, Abstract #55.
147. Schally A.V., Arimura A., Baba Y., Nair R.M.G., Matsuo H., Redding T.W., Debeljuk L., White W.F. Isolation and properties of the FSH- and LH-releasing hormone. Biochem Biophys Res Commun. 43:1971;393-399.
148. Schally A.V., Arimura A., Kastin A.J., Matsuo H., Baba Y., Redding T.W., Nair R.M.G., Debeljuk L., White W.F. Gonadotropin-releasing hormone one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones . Science. 173:1971;1036-1038.
149. Schally A.V., Bajusz S., Redding T.W., Zalatnai A., Comaru-Schally A.M. Analogs of LHRH the present and the future . Vickery B.H., Lunenfeld V. GnRH analogs in Cancer and in Human Reproduction. Basic Aspects, Vol. 1. 1989;5-31 Kluwer Academic, Dordrecht.
150. Schally A.V., Comaru-Schally A.M. Hypothalamic and other peptide hormones. Chapter 71. Holland J.F., Frei E., Bast R.C., Kufe D.E., Morton D.L., Weichselbaum R.R. Cancer Medicine, 4th Ed. 1997;1067-1086 Williams and Wilkins, Baltimore.
151. Schally A.V., Comaru-Schally A.M., Gonzalez-Barcena D., Reissmann T., Engel J. Antagonistic analogs of LHRH in oncology and gynecology. Minaguchi H., Sugimoto O. Endometriosis Today Advances in Research and Practice. Proceedings of the Vth World Congress on Endometriosis, Yokohama, Japan, October 1996 . 1997;401-413 Parthenon, Carnforth, UK.
152. Schally A.V., Kastin A.J. Stimulation and inhibition of fertility through hypothalamic agents. Drug Ther. 1:1971;29-32.
153. Schally A.V., Kastin A.J., Arimura A. Hypothalamic FSH and LH-regulating hormone, structure, physiology, and clinical studies. Fertil Steril. 22:1971;703-721.
154. Schally A.V., Kastin A.J., Arimura A. FSH-releasing hormone and LH-releasing hormone. Vitam Horm. 30:1972;83-164.
155. Schally A.V., Kastin A.J., Coy D.H., Edward T. Tyler Prize Oration - LH-releasing hormone and its analogs recent basic and clinical investigations . Int J Fertil. 21:1976;1-30.
156. Schally A.V., McCann S.M. The privileges of a Nobel Laureate. Fertil Steril. 64:1995;452-453.
157. Schally A.V., Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Eur J Endocrinol. 141:1999;1-14.
158. Schally A.V., Nagy A., Szepeshazi K., Pinski J., Halmos G., Armatis P., Miyazaki M., Comaru-Schally A.M., Yano T., Emons G. LH-RH analogs with cytotoxic radicals. Filicori M., Flamigni C. Treatment with GnRH Analogs Controversies & Perspectives. A Satellite Symposium of 15th World Congress of Fertility & Sterility, Bologna, Italy, September 15-16, 1995 . 1996;33-44 Parthenon, Carnforth, UK.
159. Schally A.V., Nair R.M.G., Redding T.W., Arimura A. Isolation of the LH- and FSH-releasing hormone from porcine hypothalami. J Biol Chem. 246:1971;7230-7236.
160. Segal-Abramson T., Kitroser H., Levy J., Schally A.V., Sharoni Y. Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Proc Natl Acad Sci USA. 89:1992;2336-2339.
161. Sharifi R., Soloway M. Leuprolide Study Group. Clinical study of leuprolide depot formulation in the treatment of advanced prostate cancer. J Urol. 143:1990;68-72.
162. Sharoni Y., Bosin E., Miinster A., Levy J., Schally A.V. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA. 86:1989;1648-1651.
163. Shirahige Y., Cook C.B., Pinski J., Halmos G., Nair R., Schally A.V. Treatment with luteinizing hormone-releasing hormone antagonist SB-75 decreases levels of epidermal growth factor receptor and its mRNA in OV-1063 human epithelial ovarian cancer xenografts in nude mice. Int J Oncol. 5:1994;1031-1035.
164. Sogani P.C., Fair W.R. Treatment of advanced prostate cancer. Urol Clin N Am. 14:1987;253-271.
165. Srkalovic G., Schally A.V., Wittliff J.L., Day G. Jr, Jenison E.L. Presence and characteristics of receptors for [D-Trp6]-luteinizing hormone-releasing hormone and epidermal growth factor in human ovarian cancer. Int J Oncol. 12:1998;489-498.
166. Srkalovic G., Wittliff J.L., Schally A.V. Detection and partial characterization of receptors for [D-Trp6]-LH-RH and EGF in human endometrial carcinoma. Cancer Res. 50:1990;1841-1846.
167. Stojilkovic S., Catt K.J. Expression and signal transduction pathways of gonadotropin releasing hormone receptors. Rec Prog Horm Res. 30:1995;161-205.
168. Styne D.M., Harris D.A., Egli C.A., Conte F.A., Kaplan S.L., Rivier J., Vale W., Grumbach M.M. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis . J Clin Endocrinol Metab. 61:1985;142-151.
169. Szende B., Srkalovic G., Groot K., Lapis K., Schally A.V. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75. J Natl Cancer Inst. 82:1990;513-517.
170. Szende B., Srkalovic G., Schally A.V., Lapis K., Groot K. Inhibitory effects of analogs of luteinizing hormone-releasing hormone (LH-RH) and somatostatin on pancreatic cancers in hamsters Events which accompany tumour regression . Cancer. 65:1990;2279-2290.
171. Szepeshazi K., Lapis K., Schally A.V. Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters. Int J Cancer. 49:1991;260-266.
172. Szepeshazi K., Schally A.V., Nagy A., Halmos G., Groot K. Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) analogs inhibit growth of estrogen-independent MXT mouse mammary cancer in vivo by decreasing cell proliferation and inducing apoptosis. Anti-Cancer Drugs. 8:1997;974-987.
173. Tolis G., Ackman D., Stellos A., Mehta A., Labrie F., Fazekas A., Comaru-Schally A.M., Schally A.V. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing agonists. Proc Natl Acad Sci USA. 79:1982;1658-1662.
174. Tom L., Bhasin S., Salameh W., Steiner B., Peterson M., Sokol R.Z., Rivier J., Vale W., Swerdloff R.S. Induction of azoospermia in normal men with combined Nal-Glu gonadotropin-releasing hormone antagonist and testosterone enanthate. J Clin Endocrinol Metab. 75:1992;476-483.
175. Ubaldi F., Albano C., Peukert M., Riethmüller-Winzen H., Camus M., Smitz J., van Steirteghem A., Devroey P. Subtle progesterone rise after the administration of the gonadotrophin-releasing hormone antagonist Cetrorelix in intracytoplasmic sperm injection cycles. Hum Reprod. 11:1996;101-103.
176. van Leusden H.A.I.M. Rapid reduction of uterine myomas after short-term treatment with microencapsulated [D-Trp6]LHRH. Lancet. 2:1986;45-51.
177. Vickery B.H. Comparison of the potential for therapeutic utilities with gonadotrophin-releasing hormone agonists and antagonists. Endocr Rev. 7:1986;115-124.
178. Walker K.J., Turkes A., Williams M.R., Blamey R.W., Nicholson R.I. Preliminary endocrinological evaluation of a sustained-release formulation of the LH-releasing hormone agonist D-Ser(But)6Azgly10LHRH in premenopausal women with advanced breast cancer. J Endocrinol. 111:1986;349-353.
179. Wildt L., Diedrich K., van der Ven H., Hasanis A.L., Hubner J., Klazen R. Ovarian hyperstimulation for in vitro fertilization controlled by GnRH agonist administration in combination with human menopausal gonadotropins. Hum Reprod. 1:1986;15-19.
180. Williams M.R., Walker K.J., Turkes A., Blamey R.W., Nicholson R.I. The use of an LHRH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer. 53:1986;629-636.
181. Yano T., Pinski J., Halmos G., Szepeshazi K., Groot K., Schally A.V. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75. Proc Natl Acad Sci USA. 91:1994;7090-7094.
182. Yano T., Pinski J., Szepeshazi K., Halmos G., Radulovic S., Groot K., Schally A.V. Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonist RC-3095 and LH-RH antagonist SB-75 on growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice. Cancer. 73:1994;1229-1238.
183. Zarate A., Canales E.S., Sthory I., Coy D.H., Comaru-Schally A.M., Schally A.V. Anovulatory effect of a LHRH antagonist in women. Contraception. 24:1981;315-320.
184. Zorn J.R., Boyer P., Guichard A. Never on a Sunday programming for IVF-ET and GIFT . Lancet. 1:1987;385-386.
185. Zorn J.R., Tanger C.H., Roger M., Grenier J., Comaru-Schally A.M., Schally A.V. Therapeutic hypogonadism induced by a delayed release preparation of microcapsules of D-Trp6-luteinizing hormone-releasing hormone a preliminary study in eight women with endometriosis . Int J Fertil. 31:1986;11-27.